Retrotope

About Retrotope

Retrotope is a biotechnology startup that operates in the healthcare sector, specifically focusing on the development of treatments for degenerative diseases. These diseases, which include conditions like Infantile Neuroaxonal Dystrophy (INAD), Friedreich's Ataxia (FA), Amyotrophic Lateral Sclerosis (ALS), and Progressive Supranuclear Palsy (PSP), are often caused by oxidative stress and cellular degeneration due to a process called lipid peroxidation (LPO). In simple terms, LPO is a harmful process where fats in our cells are damaged, leading to cell degeneration and various diseases.

Retrotope's business model revolves around the development and commercialization of proprietary therapeutics designed to combat these diseases. They do this by reducing LPO, thereby protecting against cellular degeneration. The company's revenue is expected to come from the sales of these therapeutics once they have been approved for use in the market.

The company is currently in various stages of clinical trials for its therapeutics. For example, they recently reported positive results from animal model studies of their RT011 therapeutic for retinal degeneration. They have also completed enrollment for a Phase 2 study of their RT001 therapeutic in patients with PSP.

In summary, Retrotope is a biotech startup that aims to combat degenerative diseases by developing novel therapeutics. Their business model is based on the sales of these therapeutics, which are currently in various stages of clinical trials.